Business
Apotex first to receive Health Canada approval for SEVMIA(TM), a generic semaglutide for chronic weight management
Apotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chro...
About this update from Apotex Health Corp.
Apotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chronic weight management Apotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chronic weight management /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; } .prngen2{ PADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; BORDER-TOP:black 1pt; BORDER-RIGHT:black 1pt; BORDER-BOTTOM:black 1pt; BORDER-LEFT:black 1pt } .prnml4{ MARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT } .prnbcc{ BORDER-COLLAPSE: COLLAPSE } PR Newswire TORONTO, June 30, 2026 /PRNewswire/ - Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), the largest Canadian-based global health company, today announced it is the first to receive Health Canada's approval for a generic equivalent of Wegovy® (semaglutide injection) for chronic weight management in adults. SEVMIA™ (semaglutide injection) is supplied as a multi-use pre-filled pen delivering doses of 1 mg (4 mg per pen; 1.34 mg/mL).This approval follows Health Canada's recent approval of Apo‑Semaglutide Injection™, and reflects Apotex's continued focus on bringing high-quality, affordable medicines to Canadians.  Together, these two medications expand the Company's portfolio across type 2 diabetes and chronic weight management. SEVMIA™ was developed in partnership with Orbicular Pharmaceutical Technologies."For more than 50 years, Apotex has helped support access to affordable medicines for Canadians," said Martin Arès, President, Apotex Canada. "This approval reflects our ongoing efforts to expand access to high-quality treatment options in areas of significant and growing needs for patients."In Canada, SEVMIA™ (semaglutide injection) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥30 kg/m²), or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, and to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and BMI ≥27 kg/m...
View stock analysis, news, and events for Apotex Health Corp.